๐ ๐๐ญ๐ข๐ฅ๐ข๐ณ๐๐ญ๐ข๐จ๐ง ๐จ๐ ๐๐๐ซ๐ค๐ข๐ง๐ฌ๐จ๐งโ๐ฌ ๐๐ข๐ฌ๐๐๐ฌ๐ ๐ฉ๐๐ญ๐ข๐๐ง๐ญ ๐ฌ๐ฉ๐๐๐ข๐๐ข๐ ๐ฌ๐๐ฆ๐ฉ๐ฅ๐๐ฌ ๐๐จ๐ซ ๐ญ๐ก๐๐ซ๐๐ฉ๐๐ฎ๐ญ๐ข๐๐ฌ ๐๐ข๐ฌ๐๐จ๐ฏ๐๐ซ๐ฒ โ ๐๐ฎ๐ง๐ญ๐๐ง๐๐จ ๐๐ง๐ข๐ฏ๐๐ซ๐ฌ๐ข๐ญ๐ฒ ๐๐ง๐ ๐๐ซ๐ ๐๐ง๐จ๐๐ก๐๐ซ๐๐ฉ๐๐ฎ๐ญ๐ข๐๐ฌ ๐ฐ๐จ๐ซ๐ค ๐ญ๐จ๐ ๐๐ญ๐ก๐๐ซ ๐ค Patient specific stem cell lines are the foundation for the development of the brain organoid model that OrganoTherapeutics uses to develop new therapeutics against Parkinsonโs disease. Hence, having available a broad spectrum of these stem cell lines from different individuals, with different PD associated mutations and different genetic backgrounds is a key prerequisite for the success of this endeavor. The newly concluded alliance between Juntendo University in Tokyo and OrganoTherapeutics, now allows OrganoTherapeutics to make use of various stem cell lines that have been generated at Juntendo. โก OrganoTherapeutics CEO, Jens Schwamborn mentions โJuntendo University is a world leading institution in PD research. Partnering with such a powerhouse is an immense honor for us. Further, the cell lines that we get from Juntendo are extremely valuable for us and will certainly accelerate our therapeutics developments. We are very grateful for this important collaboration.โ โก Chair and Professor of Juntendo University, Nobutaka Hattori mentions โWe work with collaborators around the world to bring better treatments to patients with Parkinson's disease. Through this partnership with OrganoTherapeutics, a frontrunner in the development of therapeutics using iPSC-derived organoids, we are excited about the development of new therapies.โ About Juntendo University: Juntendo University was founded in 1838 as the oldest Western medical school in Japan. The Department of Neurology at Juntendo University has focused on the treatment and research of Parkinson's disease for many years. They have made many research contributions, including the discovery of three PARK PD-related genes, a blood-based PD diagnostic method, and studies using patient-derived iPS cells. Their goal is to provide more optimal treatment for all patients through the development of these studies. About OrganoTherapeutics: OrganoTherapeutics (OT) is a spin-off biotech company from the University of Luxembourg and the Luxembourg center for Systems Biomedicine. Founded in 2019, OT aims at further developing brain organoid systems and using them for therapeutics development in Parkinsonโs disease. The OT approach is based on phenotypic screening and AI based data analysis. The company is well embedded in the Luxembourgish research landscape, collaborates with leading institutions through European networks and has established partnerships with universities, biotech and pharma companies in Europe, Japan and the US. #collaboration #parkinsonsdisease #therapeutics ย
OrganoTherapeuticsโ Post
More Relevant Posts
-
๐๐ฒ๐ฎ๐น๐๐ต๐ฐ๐ฎ๐ฟ๐ฒ | ๐ฃ๐ต๐ฎ๐ฟ๐บ๐ฎ๐ฐ๐ฒ๐๐๐ถ๐ฐ๐ฎ๐น๐ | ๐ ๐ฒ๐ฑ๐ถ๐ฐ๐ฎ๐น ๐๐ฒ๐๐ถ๐ฐ๐ฒ๐ & ๐ฆ๐๐ฝ๐ฝ๐น๐ถ๐ฒ๐ | ๐๐ถ๐ฎ๐ด๐ป๐ผ๐๐๐ถ๐ฐ๐ ๐ฎ๐ป๐ฑ ๐๐ถ๐ผ๐๐ฒ๐ฐ๐ต | ๐๐ถ๐ณ๐ฒ ๐ฆ๐ฐ๐ถ๐ฒ๐ป๐ฐ๐ฒ๐
A complete study of ๐๐ญ๐๐ฆ ๐๐๐ฅ๐ฅ ๐๐ก๐๐ซ๐๐ฉ๐ฒ [PDF Data] ๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐ ๐ ๐ซ๐๐ ๐๐๐ ๐๐จ๐ฉ๐ฒ: https://lnkd.in/dHR3TQZE (Please prefer the corporate mail ID to get the highest priority) The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Market growth is driven mainly by factors such as robust funding for stem cell research, an increase in the number of cell therapy production facilities that have GMP certification, and growth in the number of clinical trials associated with stem cell therapies. The surge in the expanding number of clinical trials is further triggered by the COVID-19 pandemic, with a vast number of clinical trials studying the potential of stem cell therapies in the treatment of SARS-CoV-2 infection. ๐บ๐๐๐ ๐ช๐๐๐ ๐ป๐๐๐๐๐๐ ๐ด๐๐๐๐๐ ๐ซ๐๐๐๐๐๐๐ ๐ซ๐๐๐๐๐: ๐จ๐๐๐๐๐๐๐๐๐๐๐ ๐๐ ๐๐๐๐ ๐๐๐ ๐๐๐ ๐๐๐๐ ๐๐๐๐ ๐๐๐๐๐๐๐๐ Stem cell research funding has strengthened in the past few years, attributed to the need for novel therapeutic interventions in patients with cardiovascular, neurological, and autoimmune disorders. The NIH funding for stem cell research reached its highest peak in 2018 and has shown a year-on-year growth of more than 5% in the stem cell research funding each year. This trend is expected to continue with the increase in funding initiatives announced in 2021. For instance, in September 2021, the California Institute for Regenerative Medicine granted a grant of USD 31 million to Stanford Research for launching first-in-human trials of stem cells in the treatment of heart failure, stroke, and spinal cord tumours. ๐ต๐๐๐๐ ๐จ๐๐๐๐๐๐ ๐๐๐ ๐๐๐ ๐๐๐๐๐๐๐ ๐๐๐๐๐๐ ๐๐๐ ๐๐๐๐ ๐๐๐๐ ๐๐๐๐๐๐๐ ๐๐๐๐๐๐. Geographically, the market is segmented into North America, Europe, Asia Pacific, and RoW (the rest of the world). In 2022, the global market was dominated by the North America region, and this dominance is anticipated to continue throughout the forecast period. The US has emerged as the key revenue contributor to this region, with robust public-private funding to develop novel stem cell therapy products. Prominent players in the stem cell therapy market include Smith+Nephew (UK), MEDIPOST Co., Ltd. (South Korea), Anterogen.Co., Ltd. (South Korea), CORESTEM (South Korea), Pharmicell Inc. (South Korea), NuVasive, Inc. (US), RTI Surgical (US), AlloSource (US), JCR Pharmaceuticals Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), Holostem Terapie Avanzate Srl (Italy), Orthofix (US), Regrow Biosciences Pvt Ltd. (India), and STEMPEUTICS RESEARCH PVT LTD. (India).
To view or add a comment, sign in
-
๐๐๐ง๐ข๐จ๐ซ ๐๐ฎ๐ฌ๐ข๐ง๐๐ฌ๐ฌ ๐๐ง๐๐ฅ๐ฒ๐ฌ๐ญ - ๐๐ก๐๐ซ๐ฆ๐๐๐๐ฎ๐ญ๐ข๐๐๐ฅ๐ฌ, & ๐๐๐๐ฅ๐ญ๐ก๐๐๐ซ๐ | ๐๐ถ๐ฎ๐ด๐ป๐ผ๐๐๐ถ๐ฐ๐ ๐ฎ๐ป๐ฑ ๐๐ถ๐ผ๐๐ฒ๐ฐ๐ต | ๐๐ถ๐ณ๐ฒ ๐ฆ๐ฐ๐ถ๐ฒ๐ป๐ฐ๐ฒ๐
A Complete Guide of " ๐๐ญ๐๐ฆ ๐๐๐ฅ๐ฅ ๐๐ก๐๐ซ๐๐ฉ๐ฒ " [ PDF Guide] ๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐ ๐ ๐ซ๐๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ฉ๐จ๐ซ๐ญ ๐๐๐ซ๐: https://lnkd.in/dQDRwEJ6 The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Market growth is driven mainly by factors such as rise in funding for stem cell research, upsurge in the number of cell therapy production facilities that have GMP certification, and increased in the number of clinical trials associated with stem cell therapies. ๐๐ซ๐ข๐ฏ๐๐ซ: ๐๐ง๐๐ซ๐๐๐ฌ๐๐ ๐๐ฎ๐ง๐๐ข๐ง๐ ๐๐จ๐ซ ๐ฌ๐ญ๐๐ฆ ๐๐๐ฅ๐ฅ ๐ซ๐๐ฌ๐๐๐ซ๐๐ก Government initiatives and funding mechanisms exert a pivotal influence on the dynamics of the market. Favorable regulatory frameworks and financial support from governmental bodies play a catalytic role in fostering an environment conducive to research and development in stem cell therapies. The need for newer and better therapies for the treatment of autoimmune, neurological, and cardiovascular diseases has resulted in an overall increase in research activities and the availability of funding for cell-based research. In December 2022, Alpha Stem Cell Clinic received an USD 8 million, five-year grant from the California Institute of Regenerative Medicine (CIRM) for the study of the use of self-renewing cells to treat human disease. Furthermore, in November 2019, the Australian government released a 10-year roadmap for stem cell research in AustraliaโThe Stem Cell Therapies Mission. The initiative would provide USD 102 million (AUD 150 million) under the Medical Research Future Fund (MRFF) to support stem cell research to deliver new therapies. The infusion of government funding not only accelerates the pace of clinical trials but also facilitates the translation of research findings into viable therapeutic applications. As a result, the stem cell therapy industry is experiencing a positive ripple effect, with increased investments leading to expanded capabilities, enhanced infrastructure, and ultimately contributing to the overall growth and maturation of the industry.
To view or add a comment, sign in
-
Bayer Breakthrough in Parkinson's Stem Cell Therapy! Exciting news from the medical world as Bayer announces a significant leap in the battle against Parkinson's disease. The experimental stem cell therapy developed by its U.S. subsidiary, BlueRock Therapeutics has shown promising results in easing Parkinson's symptoms during an early 12-patient trial. ๐ Key Highlights: - 12 patients underwent the trial: seven on a high dose and five on a lower dose. - High dose participants reported an average of 2.16 hours longer with well-controlled symptoms per day, while the time of worsening symptoms was cut by 1.91 hours. - Lower dose participants experienced an average of 0.72 hours longer with controlled symptoms and 0.75 hours less of worsening symptoms. - No major safety issues were encountered. The treatment was well-tolerated. The therapy involves transforming human pluripotent embryonic stem cells into dopamine-producing nerve cells, which are then implanted into the brain. The results were shared at the International Congress of Parkinson's Disease and Movement Disorders in Copenhagen, Denmark. Bayer plans to move forward with testing in the second of three stages, with patient enrolment set to begin in the first half of 2024. Bayer's advancements in this area provide hope to over 10 million Parkinson's patients worldwide. As research progresses, we look forward to more breakthroughs in the quest for a cure. https://lnkd.in/eZMTfVpZ #ParkinsonsResearch #StemCellTherapy #MedicalBreakthroughs #BayerUpdates
To view or add a comment, sign in
-
(Pluripotent) Stem Cells | iPS Cells | ES Cells | Early Discovery | Cell Therapy | Regenerative Medicine | Precision Medicine | Drug Screening Platform(s) | Aging & Longevity | ๐จ๐ฆ in ๐บ๐ธ
Stem Cell Therapy Landscape: Last Episode Next series: Stem cells and Cultured meat The journey of stem cells from research labs to bedside treatments is a complex one, riddled with intricate technical challenges. A primary concern is the transition from academic bench protocols, which are often manual and small-scale, to robust, industrial-scale systems that adhere to Good Manufacturing Practices (GMP). This shift demands not only scalability but also a consistent and sustainable approach to ensure the quality and efficacy of the therapies. Innovative techniques, such as 3D mid-to-large scale bioprocessing, are being explored to produce human iPSC-derived cortical neurons more efficiently. These processes aim to enhance cell yield, purity, and functionality, which are crucial for therapeutic applications. Furthermore, the integration of AI and machine learning offers promising avenues to streamline and optimize the iPSC manufacturing process, from cell sourcing to differentiation and quality control. However, with these advancements come challenges. Ensuring that these high-tech processes maintain the integrity and safety of the stem cells, while also being scalable for clinical demands, is a delicate balance. As the field progresses, it's imperative to address these technical hurdles head-on, laying a solid foundation for the successful clinical translation of stem cell therapies. https://lnkd.in/gX2pYsXT
Autologous Induced Pluripotent Stem CellโBased Cell Therapies: Promise, Progress, and Challenges
currentprotocols.onlinelibrary.wiley.com
To view or add a comment, sign in
1,054 followers
Congrats OT